Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma,
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
EJ Jordan, HR Kim, ME Arcila, D Barron… - Cancer …, 2017 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Tumor genetic testing is standard of care for
patients with advanced lung adenocarcinoma, but the fraction of patients who derive clinical …
patients with advanced lung adenocarcinoma, but the fraction of patients who derive clinical …
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
EJ Jordan, HR Kim, ME Arcila, D Barron… - Cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma,
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
EJ Jordan, HR Kim, ME Arcila, D Barron… - Cancer …, 2017 - ohiostate.elsevierpure.com
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma,
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
[HTML][HTML] Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies
EJ Jordan, HR Kim, ME Arcila, D Barron… - Cancer …, 2017 - ncbi.nlm.nih.gov
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
EJ Jordan, HR Kim, ME Arcila, D Barron… - Cancer …, 2017 - europepmc.org
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies.
EJ Jordan, HR Kim, ME Arcila, D Barron… - Cancer …, 2017 - europepmc.org
Tumor genetic testing is standard of care for patients with advanced lung adenocarcinoma
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …
but the fraction of patients who derive clinical benefit remains undefined. Here, we report the …